Heptamethoxyflavone

Heptamethoxyflavone is a polymethoxylated flavone found primarily in citrus peel that exhibits multidrug resistance modulation and kinase inhibition activity. Its primary mechanisms involve inhibiting ATP-binding cassette efflux transporters such as ABCG2 and P-glycoprotein 1, potentially enhancing intracellular drug accumulation in cancer cell models.

Origin & History

Heptamethoxyflavone is a polymethoxylated flavone, part of the flavonoid group, found naturally in plants of the Rutaceae family such as Citrus reticulata and Citrus sinensis. It is typically extracted using solvents like chloroform or ethyl acetate, resulting in a yellow powder with ≥95% purity via HPLC standardization.

Historical & Cultural Context

There are no documented historical or traditional medicinal uses for heptamethoxyflavone in the research provided. Its use is primarily based on its presence in certain citrus plants.

Health Benefits

• May modulate multidrug resistance via efflux pump inhibition, as shown by in vitro studies on ABCG2 and P-glycoprotein 1, though human clinical trials are lacking.[1] • Potentially influences gene expression and kinase activity by targeting proteins like dual specificity protein phosphatase 3 and Kruppel-like factor 5, although these are predicted targets not validated experimentally.[1] • Shows inhibition of DNA topoisomerase II alpha, suggesting a role in transcriptional regulation, albeit without direct human evidence.[1] • Predicted to impact oxidative stress responses via NRF2, based on computational models, but not confirmed in vivo.[1] • Could affect drug metabolism through pregnane X receptor interaction, yet this remains a theoretical benefit without clinical validation.[1]

How It Works

Heptamethoxyflavone inhibits ATP-binding cassette transporters ABCG2 and P-glycoprotein 1, reducing efflux of substrates from cells and potentially reversing multidrug resistance phenotypes in vitro. It also targets dual specificity protein phosphatase 3 (DUSP3), modulating downstream MAPK and ERK signaling cascades that regulate cell proliferation and survival. Additionally, its seven methoxy substituents on the flavone backbone enhance lipophilicity, facilitating membrane permeability and interaction with intracellular kinase targets.

Scientific Research

No human clinical trials or meta-analyses have been conducted on heptamethoxyflavone. Current evidence is limited to in vitro assays with IC50 values for ABCG2 and P-glycoprotein 1.[1] No PMIDs available for human studies.

Clinical Summary

Research on heptamethoxyflavone is predominantly limited to in vitro cell-based studies and computational docking analyses, with no published randomized controlled human clinical trials as of 2024. In vitro studies using cancer cell lines have demonstrated inhibition of ABCG2-mediated drug efflux at micromolar concentrations, suggesting theoretical utility in overcoming chemotherapy resistance. Animal pharmacokinetic data on structurally related polymethoxylated flavones indicate moderate oral bioavailability and hepatic metabolism, though species-specific differences complicate direct human extrapolation. The overall evidence base is preliminary, and efficacy and safety conclusions for human supplementation cannot be drawn from current data.

Nutritional Profile

Heptamethoxyflavone (5,6,7,8,3',4',5'-heptamethoxyflavone; C₂₂H₂₄O₉; MW ~436.4 g/mol) is a polymethoxylated flavone, not a macronutrient source. It provides negligible calories, protein, fat, fiber, or carbohydrates at bioactive doses. Key details: • **Bioactive classification:** Polymethoxylated flavone (PMF), structurally related to nobiletin (hexamethoxyflavone) and tangeretin (pentamethoxyflavone). Distinguished by having seven methoxy (–OCH₃) substituents on the flavone backbone at positions 5, 6, 7, 8, 3', 4', and 5'. • **Natural occurrence & approximate concentrations:** Found predominantly in Citrus species peels, particularly in Kaempferia parviflora (black ginger) rhizome and certain citrus peel extracts. Concentrations in citrus peel oils/extracts are typically low, estimated at ~0.01–0.5% of dried peel weight depending on cultivar, extraction method, and tissue. In Kaempferia parviflora extracts, PMFs including heptamethoxyflavone may constitute roughly 1–5% of standardized ethanolic extracts. • **Vitamins & minerals:** None intrinsic; heptamethoxyflavone is a single phytochemical, not a whole-food matrix. • **Bioavailability notes:** Oral bioavailability is expected to be low-to-moderate, consistent with other polymethoxylated flavones. The seven methoxy groups increase lipophilicity (estimated logP ~2.5–3.5) compared to hydroxylated flavonoids, which generally improves membrane permeability and metabolic stability relative to polyhydroxylated analogs. However, first-pass hepatic metabolism (CYP450-mediated O-demethylation) and intestinal efflux (P-glycoprotein, ABCG2 substrates) likely limit systemic exposure. Co-administration with lipids or formulation in nanoemulsions/liposomes may enhance absorption. Plasma half-life data in humans are not well established; rodent studies on related PMFs suggest t½ of ~1–4 hours. Metabolites (demethylated and glucuronidated forms) may retain partial biological activity. • **Typical study doses (preclinical context):** In vitro studies commonly use 1–100 µM; in vivo rodent studies typically administer 10–50 mg/kg body weight orally. No established human dosing exists. • **No significant macro- or micronutrient contribution** at pharmacologically relevant doses (estimated human-equivalent doses would be in the range of ~50–500 mg/day based on allometric scaling from rodent data, providing essentially zero nutritional energy).

Preparation & Dosage

There are no clinically studied dosage ranges or forms available for heptamethoxyflavone, as human trials are absent in the current research. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Naringenin, Quercetin, Resveratrol, Apigenin, Hesperidin

Safety & Interactions

No human clinical safety data specific to heptamethoxyflavone supplementation are currently available, making formal risk characterization difficult. Because it inhibits P-glycoprotein 1 and ABCG2 transporters, concurrent use with P-gp or BCRP substrate drugs such as digoxin, rosuvastatin, or certain chemotherapeutics could theoretically increase plasma drug levels and toxicity risk. Polymethoxylated flavones as a class are metabolized via cytochrome P450 enzymes including CYP1A2 and CYP3A4, suggesting possible interactions with medications sharing these metabolic pathways. Use during pregnancy or lactation is not recommended due to the complete absence of safety data in these populations.